• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

COVID-19 大流行：我们的医学仍然是基于证据的吗？

The COVID-19 pandemic: is our medicine still evidence-based?

机构信息

Anesthesia and Intensive Care 1, Department of Anesthesia and Intensive Care, Academic Hospital of Udine, Udine, Italy.

出版信息

Ir J Med Sci. 2021 Feb;190(1):11-12. doi: 10.1007/s11845-020-02258-8. Epub 2020 May 28.

DOI:10.1007/s11845-020-02258-8
PMID:32468413
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8824855/
Abstract

There is no randomized controlled trial that demonstrated the efficacy of antiviral therapy against COVID-19 yet. However, physicians are prescribing different drugs to a large part of COVID-19 population in the hope they will cure them. This does not reflect the evidence-based medicine approach. What we need is more evidence-based knowledge about what routine care practices we should to apply to ameliorate symptoms of patients and fight COVID-19 pathology.

摘要

目前还没有随机对照试验证明抗病毒疗法对 COVID-19 的疗效。然而，医生们正在给很大一部分 COVID-19 患者开不同的药物，希望能治愈他们。这不符合循证医学的方法。我们需要更多基于循证的知识，了解我们应该应用哪些常规护理措施来改善患者的症状和对抗 COVID-19 病理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73dd/8824855/7bdafeb67aa6/11845_2020_2258_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73dd/8824855/7bdafeb67aa6/11845_2020_2258_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73dd/8824855/7bdafeb67aa6/11845_2020_2258_Fig1_HTML.jpg

相似文献

1
The COVID-19 pandemic: is our medicine still evidence-based?COVID-19 大流行：我们的医学仍然是基于证据的吗？
Ir J Med Sci. 2021 Feb;190(1):11-12. doi: 10.1007/s11845-020-02258-8. Epub 2020 May 28.
2
Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Aditional Benefit.瑞德西韦治疗 COVID-19：肺部和静脉联合给药可能提供额外益处。
AAPS J. 2020 May 26;22(4):77. doi: 10.1208/s12248-020-00459-8.
3
Randomized  Controlled Trials Versus Real-World Data in the COVID-19 Era: A False Narrative.新冠疫情时代的随机对照试验与真实世界数据：一种错误的说法。
Cancer Invest. 2020 Nov;38(10):537-542. doi: 10.1080/07357907.2020.1841922. Epub 2020 Nov 5.
4
Clinical trials and the COVID-19 pandemic.临床试验与新冠疫情
Hell J Nucl Med. 2020 Jan-Apr;23(1):4-5. doi: 10.1967/s002449912014.
5
[Fight against COVID-19: market overview and pipeline of ongoing trials].抗击新冠疫情：市场概述与正在进行的试验进展
Med Sci (Paris). 2020 Dec;36(12):1225-1232. doi: 10.1051/medsci/2020231. Epub 2020 Nov 19.
6
Will COVID-19 be evidence-based medicine's nemesis?新冠病毒肺炎会成为循证医学的克星吗？
PLoS Med. 2020 Jun 30;17(6):e1003266. doi: 10.1371/journal.pmed.1003266. eCollection 2020 Jun.
7
Implementation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 (REMAP-COVID) trial in a US health system-lessons learned and recommendations.在美国医疗体系中实施 COVID-19 随机嵌入式多因素适应性平台试验（REMAP-COVID）：经验教训和建议。
Trials. 2021 Jan 28;22(1):100. doi: 10.1186/s13063-020-04997-6.
8
Ethics of clinical research and practice in India during the Covid-19 pandemic.印度新冠疫情期间临床研究与实践的伦理问题。
Indian J Med Ethics. 2020 Jul-Sep;V(3):175-180. doi: 10.20529/IJME.2020.080.
9
Clinical Trials of Repurposed Antivirals for SARS-CoV-2.抗 SARS-CoV-2 再利用抗病毒药物的临床试验。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01101-20.
10
Two Key Takeaways From a Year of Pandemic Research.疫情研究一年的两个关键要点。
Crit Care Med. 2021 Aug 1;49(8):1223-1226. doi: 10.1097/CCM.0000000000005078.

引用本文的文献

1
Insights into neurological dysfunction of critically ill COVID-19 patients.对危重症新冠病毒疾病患者神经功能障碍的见解
Trends Anaesth Crit Care. 2021 Feb;36:30-38. doi: 10.1016/j.tacc.2020.09.005. Epub 2020 Sep 15.
2
Observational study of clinico-radiological follow-up of COVID-19 pneumonia: a district general hospital experience in the UK.观察性研究：英国地区综合医院对 COVID-19 肺炎的临床-放射学随访经验。
BMC Infect Dis. 2021 Dec 8;21(1):1233. doi: 10.1186/s12879-021-06941-8.
3
The Use of Tocilizumab in Patients with COVID-19: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Studies.

本文引用的文献

1
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.瑞德西韦治疗成人重症 COVID-19 的随机、双盲、安慰剂对照、多中心临床试验。
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.
2
A real-time dashboard of clinical trials for COVID-19.新冠肺炎临床试验实时信息平台。
Lancet Digit Health. 2020 Jun;2(6):e286-e287. doi: 10.1016/S2589-7500(20)30086-8. Epub 2020 Apr 24.
3
Evidence based medicine - new approaches and challenges.循证医学——新方法与挑战。
托珠单抗在新型冠状病毒肺炎患者中的应用：随机对照研究的系统评价、Meta分析及试验序贯分析
J Clin Med. 2021 Oct 25;10(21):4935. doi: 10.3390/jcm10214935.
4
Pericardial Cytokine "Storm" in a COVID-19 Patient: the Confirmation of a Hypothesis.COVID-19 患者的心包细胞因子“风暴”：假设的验证。
Inflammation. 2022 Feb;45(1):1-5. doi: 10.1007/s10753-021-01563-3. Epub 2021 Sep 17.
5
SARS-CoV-2 and Acute Cerebrovascular Events: An Overview.严重急性呼吸综合征冠状病毒2与急性脑血管事件：概述
J Clin Med. 2021 Jul 29;10(15):3349. doi: 10.3390/jcm10153349.
6
Transition from Simple V-V to V-A and Hybrid ECMO Configurations in COVID-19 ARDS.新冠病毒感染所致急性呼吸窘迫综合征中从单纯静脉-静脉到静脉-动脉及混合体外膜肺氧合配置的转变
Membranes (Basel). 2021 Jun 9;11(6):434. doi: 10.3390/membranes11060434.
7
Intensive care unit discharge: mind the gap!重症监护病房出院：注意差距！
BMC Anesthesiol. 2021 Feb 8;21(1):40. doi: 10.1186/s12871-021-01251-7.
8
A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort.一种治疗新冠肺炎患者的新方法；洛匹那韦加强力霉素队列研究结果
Eur J Clin Microbiol Infect Dis. 2021 Mar;40(3):663-664. doi: 10.1007/s10096-020-04112-2. Epub 2021 Jan 7.
Acta Inform Med. 2008;16(4):219-25. doi: 10.5455/aim.2008.16.219-225.